Treatment of Wilson's Disease

Editorials1 September 1983Treatment of Wilson's DiseaseANDREW DEISS, M.D.ANDREW DEISS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-99-3-398 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe goal of treatment of Wilson's disease is to increase copper excretion. In view of the ample evidence that the symptoms of Wilson's disease are due to damage caused by excess copper, this approach is an obvious and reasonable one. Because several agents that effectively establish a negative copper balance have been developed over the past three decades, a potential exists for considerable flexibility in the treatment of Wilson's disease. Other goals in successful therapy for these patients deserve attention, however, and these may be more important than the development of new copper chelating agents.The effort to develop effective...References1. CUMINGS J. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain. 1948;71:410-5. CrossrefMedlineGoogle Scholar2. CUMINGS J. The effects of BAL in hepatolenticular degeneration. Brain. 1951;74:10-22. CrossrefMedlineGoogle Scholar3. DENNY-BROWNPORTER DH. The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl J Med. 1951;245:917-25. CrossrefMedlineGoogle Scholar4. WALSHE J. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487-95. CrossrefMedlineGoogle Scholar5. WALSHE J. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent. Lancet. 1969;2:1401-2. CrossrefMedlineGoogle Scholar6. WALSHE J. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1:643-7. CrossrefMedlineGoogle Scholar7. EPSTEINSHERLOCK OS. Triethylene tetramine dihydrochloride toxicity in primary biliary cirrhosis. Gastroenterology. 1980;78:1442-5. CrossrefMedlineGoogle Scholar8. BREWERHILLPRASADCOSSACKRABBANI GGAZP. Oral zinc therapy for Wilson's disease. Ann Intern Med. 1983;99:314-20. LinkGoogle Scholar9. HOOGENRAABKOEVOETDE RUYTER KORVER TRE. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol. 1979;18:205-11. CrossrefMedlineGoogle Scholar10. CHANCUSHINGCOFFMANRENNERT WWMO. Genetic expression of Wilson's disease in cell culture: a diagnostic marker. Science. 1980;208:299-300. CrossrefMedlineGoogle Scholar11. SURAVANSHADOWENMCCALLZOLLMANHARDY LSCJPR. A comparison of copper-loading disease in Bedlington terriers and Wilson's disease in humans. Am J Physiol. 1982;243:G226-30. MedlineGoogle Scholar12. CARTWRIGHT G. Diagnosis of treatable Wilson's disease. N Engl J Med. 1978;298:1347-50. CrossrefMedlineGoogle Scholar13. SCHEINBERG I. Penicillamine in Wilson's disease [Letter]. Lancet. 1982;2:1469. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ANDREW DEISS, M.D.Affiliations: Veterans Administration Medical Center University of Utah School of Medicine Salt Lake City, Utah PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byWilson's diseaseZinc Acetate Treatment in Wilson's DiseaseZinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamineManagement of an oroantral fistula in a patient with Wilson's disease: Case report and review of the literatureEffect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.Factors Modifying the Prognosis of Wilson's Disease in ChildhoodWilson's disease: clinical presentation and use of prognostic index.ReferencesZinc Treatment of Wilson's DiseaseGEORGE J. BREWER, M.D., GRETCHEN M. HILL, PH.D., ANANDA S. PRASAD, M.D., PARVIZ RABBANI, PH.D. 1 September 1983Volume 99, Issue 3Page: 398-400KeywordsExcretion ePublished: 1 December 2008 Issue Published: 1 September 1983 PDF downloadLoading ...